Management of severe heart failure

Shinya Hiramitsu, Kenji Miyagishima, Hisashi Kimura, Kazumasa Mori, Kenji Shiino, Akira Yamada, Shigeru Kato, Yasuchika Kato, Shin Ichiro Morimoto, Hitoshi Hishida, Yukio Ozaki

研究成果: Review article査読

7 被引用数 (Scopus)

抄録

Patients admitted to the hospital with heart failure (HF) include those with new-onset of acute HF and those with acute exacerbation of chronic HF (CHF). In therapy for new-onset acute HF associated with acute myocardial infarction, therapy to inhibit left ventricular (LV) remodeling in the convalescent phase is required in addition to that needed to overcome the acute phase. Hitherto, CHF therapy was aimed at improving LV contractability, whereas more recently the aim has shifted to resting the heart. Most patients with HF should be routinely managed with a combination of 3 types of drugs: a diuretic; an angiotensin converting enzyme inhibitor and/or an angiotensin II receptor blocker; and a β-blocker. The administration of β-blockers is of particular importance. For HF unresponsive to medical therapy, non-pharmacological therapies are considered. When a HF patient fails to respond to all available therapies, heart transplantation becomes necessary. Of the 1,000 HF patients admitted to our hospital, two cases received heart transplants. 11 cases were indicated for heart transplantation but died before registration. It should be remembered that although in Japan the possibility of receiving a heart transplant is very low, it is by no means entirely impossible.

本文言語English
ページ(範囲)A36-A41
ジャーナルCirculation Journal
73
SUPPL. A
DOI
出版ステータスPublished - 2009

All Science Journal Classification (ASJC) codes

  • 循環器および心血管医学

フィンガープリント

「Management of severe heart failure」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル